These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 12424771)
1. Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers. Muller F; Thibaud D; Poloce F; Gelineau MC; Bernard M; Brochet C; Millet C; Réal JY; Dommergues M Prenat Diagn; 2002 Nov; 22(11):1036-9. PubMed ID: 12424771 [TBL] [Abstract][Full Text] [Related]
3. [How to improve the screening and diagnosis of fetal aneuploidy?]. Ville Y Bull Acad Natl Med; 2005 Nov; 189(8):1773-84; discussion 1784-7. PubMed ID: 16737102 [TBL] [Abstract][Full Text] [Related]
4. Revisiting the fetal loss rate after second-trimester genetic amniocentesis: a single center's 16-year experience. Odibo AO; Gray DL; Dicke JM; Stamilio DM; Macones GA; Crane JP Obstet Gynecol; 2008 Mar; 111(3):589-95. PubMed ID: 18310360 [TBL] [Abstract][Full Text] [Related]
5. Pregnancy outcome following second-trimester amniocentesis: a case-control study. Müngen E; Tütüncü L; Muhcu M; Yergök YZ Am J Perinatol; 2006 Jan; 23(1):25-30. PubMed ID: 16450269 [TBL] [Abstract][Full Text] [Related]
6. First trimester predictors of adverse pregnancy outcomes. Brameld KJ; Dickinson JE; O'Leary P; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038 [TBL] [Abstract][Full Text] [Related]
7. Advanced maternal age as a sole indication for genetic amniocentesis; risk-benefit analysis based on a large database reflecting the current common practice. Bornstein E; Lenchner E; Donnenfeld A; Barnhard Y; Seubert D; Divon MY J Perinat Med; 2009; 37(2):99-102. PubMed ID: 18999912 [TBL] [Abstract][Full Text] [Related]
8. The identification of risk of spontaneous fetal loss through second-trimester maternal serum screening. Huang T; Owolabi T; Summers AM; Meier C; Wyatt PR Am J Obstet Gynecol; 2005 Aug; 193(2):395-403. PubMed ID: 16098861 [TBL] [Abstract][Full Text] [Related]
9. How important is consent in maternal serum screening for Down syndrome in France? Information and consent evaluation in maternal serum screening for Down syndrome: a French study. Favre R; Duchange N; Vayssière C; Kohler M; Bouffard N; Hunsinger MC; Kohler A; Mager C; Neumann M; Vayssière C; Viville B; Hervé C; Moutel G Prenat Diagn; 2007 Mar; 27(3):197-205. PubMed ID: 17238219 [TBL] [Abstract][Full Text] [Related]
10. [Evaluation of the third trimester amniocentesis for fetal karyotyping in women with fear of pregnancy loss]. Picone O; Fuchs F; Sénat MV; Brisset S; Tachdjian G; Audibert F; Fernandez H; Frydman R J Gynecol Obstet Biol Reprod (Paris); 2008 Jun; 37(4):385-91. PubMed ID: 18191913 [TBL] [Abstract][Full Text] [Related]
11. [Serum screening of fetal chromosome abnormality during second pregnancy trimester: results of 26,803 pregnant women in Jiangsu Province]. Hu YL; Zhonghua Yi Xue Za Zhi; 2007 Sep; 87(35):2476-80. PubMed ID: 18067809 [TBL] [Abstract][Full Text] [Related]
12. Individual risk of fetal loss following routine second trimester amniocentesis: a controlled study of 20,460 cases. Kozlowski P; Knippel A; Stressig R Ultraschall Med; 2008 Apr; 29(2):165-72. PubMed ID: 17602371 [TBL] [Abstract][Full Text] [Related]
13. Modifying risk for aneuploidy with second-trimester ultrasound after a positive serum screen. Timms D; Campbell WA Clin Lab Med; 2010 Sep; 30(3):677-92. PubMed ID: 20638581 [TBL] [Abstract][Full Text] [Related]
14. Prediction of patient-specific risk for fetal loss using maternal characteristics and first- and second-trimester maternal serum Down syndrome markers. Dugoff L; Cuckle HS; Hobbins JC; Malone FD; Belfort MA; Nyberg DA; Comstock CH; Saade GR; Eddleman KA; Dar P; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME; Am J Obstet Gynecol; 2008 Sep; 199(3):290.e1-6. PubMed ID: 18771987 [TBL] [Abstract][Full Text] [Related]
15. [Pregnancy complications with abnormal results of biochemical screening for Down syndrome in second trimester and normal fetal karyotype]. Dimitrova V; Chernev T; Vragaleva S; Slŭncheva B; Mikhaĭlova E; Kremenski I; Simeonov E Akush Ginekol (Sofiia); 2002; 41(6):3-12. PubMed ID: 12577497 [TBL] [Abstract][Full Text] [Related]
16. Fetal loss after amniocentesis in a series of 5,780 procedures. Gaudry P; Grangé G; Lebbar A; Choiset A; Girard S; Goffinet F; Lewin F Fetal Diagn Ther; 2008; 23(3):217-21. PubMed ID: 18417981 [TBL] [Abstract][Full Text] [Related]
17. Fear of pregnancy loss and fetal karyotyping: a place for third-trimester amniocentesis? Picone O; Senat MV; Rosenblatt J; Audibert F; Tachdjian G; Frydman R Fetal Diagn Ther; 2008; 23(1):30-5. PubMed ID: 17934295 [TBL] [Abstract][Full Text] [Related]
18. Down syndrome screening in Singapore--the effectiveness of a second trimester serum screening policy modelled on 29,360 pregnancies in KK Women's and Children's Hospital. Lai FM; Yeo GS Singapore Med J; 1998 Feb; 39(2):69-75. PubMed ID: 9652180 [TBL] [Abstract][Full Text] [Related]
19. Adverse pregnancy outcomes after a false-positive second trimester serum screen for Down syndrome in Thai pregnant women. Sritippayawan S; Vachirasrisoontra C J Med Assoc Thai; 2005 Apr; 88(4):449-54. PubMed ID: 16146246 [TBL] [Abstract][Full Text] [Related]
20. Late first-trimester invasive prenatal diagnosis: results of an international randomized trial. Philip J; Silver RK; Wilson RD; Thom EA; Zachary JM; Mohide P; Mahoney MJ; Simpson JL; Platt LD; Pergament E; Hershey D; Filkins K; Johnson A; Shulman LP; Bang J; MacGregor S; Smith JR; Shaw D; Wapner RJ; Jackson LG; Obstet Gynecol; 2004 Jun; 103(6):1164-73. PubMed ID: 15172848 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]